Patrick Roberts
CEO,
Incyclix Bio, LLC
United States
Patrick Roberts, Chief Executive Officer at Incyclix Bio, most recently served as the head of translational medicine at G1 Therapeutics. His scientific, operational and leadership contributions helped G1 grow from an incubated start-up to a publicly traded company with three compounds in clinical development. His early scientific contributions laid the foundation for the myelopreservation concept and during his time as project leader, he had the unique opportunity to guide COSELA® (trilaciclib) from discovery to patients. Dr. Roberts has a breadth of drug development experience spanning from proof-of-concept biology through NDA submission.
Dr. Roberts obtained his clinical pharmacy training at the University of Kentucky College of Pharmacy. He continued his education in the laboratory of Dr. Channing Der at the University of North Carolina School of Pharmacy where he obtained his PhD in Pharmaceutical Sciences with an emphasis on Experimental Therapeutics. He then completed his postdoctoral training with Dr. Norman Sharpless, where he was an American Cancer Society Postdoctoral Fellow.
Suffix
PhD
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}